Table 3.

Time-to-treatment discontinuation and overall survival in patient subgroups

Patient subgroups (n of events/n)	TTD months (median, 95% CI range)	p
Age < 65 (57/124)	21.6 (17.5–25.6)	0.63
Age ≥ 65 (18/39)	19.2 (8.3–30.1)
Female (39/97)	24 (19.6–28.4)	0.021
Male (36/66)	15.1 (7.6–22.6)
Nonsmoker (49/113)	21.6 (17.3–25.9)	0.13
Smoking history (26/50)	16 (3–28.9)
2nd line osimertinib (40/96)	22.7 (14.7–30.7)	0.81
≥ 3rd line osimertinib (33/61)	21.6 (17.1–26)
Exon 19 deletion (50/112)	25.3 (21.1–29.5)	0.045
Exon 21 L858R (20/37)	15.1 (5.4–24.9)
Brain metastasis ( −) (49/114)	24 (19.4–28.6)	0.045
Brain metastasis ( +) (26/49)	11.4 (6.2–16.7)

Patient subgroups (n of events/n)	OS months (median, 95% CI range)	p
Age < 65 (37/124)	35.5 (23.8–47.1)	0.18
Age ≥ 65 (14/39)	32.1 (22.1–42.2)
Female (26/97)	35.5 (22.1–48.8)	0.063
Male (25/66)	24.2 (14.5–34)
Nonsmoker (31/113)	35.5 (21.4–49.5)	0.038
Smoking history (20/50)	27.7 (15.9–39.4)
2nd line osimertinib (29/96)	27.7 (22.7–32.7)	0.35
≥ 3rd line osimertinib (20/61)	32.1 (19–45.3)
Exon 19 deletion (32/112)	32.1 (26.5–37.8)	0.075
Exon 21 L858R (15/37)	20.1 (18.1–22.2)
Brain metastasis ( −) (31/114)	32.1 (26.5–37.8)	0.021
Brain metastasis ( +) (20/49)	17.3 (13.9–20.7)